Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth
May 16
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedMay 25, 2025
DataAggregated Company Financials
Companies28
- 7D-7.1%
- 3M-20.8%
- 1Y-28.8%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 7.1%, driven by a pullback from Mayne Pharma Group of 26%. On the other hand Argenica Therapeutics is actually up 14%. The industry has fallen 29% in the last year. As for the next few years, earnings are expected to grow by 41% per annum.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 26 May 2025 | AU$4.4b | AU$1.0b | -AU$238,266,485.00 | 17.6x | -18.5x | 4.2x |
| Wed, 23 Apr 2025 | AU$4.1b | AU$1.0b | -AU$238,266,485.00 | 16.9x | -17.2x | 3.9x |
| Fri, 21 Mar 2025 | AU$5.0b | AU$1.1b | -AU$289,508,485.00 | 18.9x | -17.2x | 4.7x |
| Sun, 16 Feb 2025 | AU$5.3b | AU$1.0b | -AU$377,002,613.00 | 14.2x | -14.1x | 5.2x |
| Tue, 14 Jan 2025 | AU$5.1b | AU$1.0b | -AU$378,981,112.00 | 12.2x | -13.6x | 5.1x |
| Thu, 12 Dec 2024 | AU$5.7b | AU$1.0b | -AU$378,981,112.00 | 13.1x | -15.1x | 5.6x |
| Sat, 09 Nov 2024 | AU$6.8b | AU$1.0b | -AU$377,703,112.00 | 14.2x | -18x | 6.7x |
| Mon, 07 Oct 2024 | AU$6.6b | AU$1.0b | -AU$377,703,112.00 | 12.9x | -17.5x | 6.5x |
| Wed, 04 Sep 2024 | AU$6.5b | AU$1.0b | -AU$383,620,117.00 | 13.4x | -16.8x | 6.3x |
| Fri, 02 Aug 2024 | AU$6.7b | AU$995.3m | -AU$387,920,108.00 | 11.1x | -17.3x | 6.7x |
| Sun, 30 Jun 2024 | AU$6.6b | AU$995.3m | -AU$387,920,108.00 | 11.5x | -16.9x | 6.6x |
| Tue, 28 May 2024 | AU$6.7b | AU$1.2b | -AU$374,923,684.00 | 14.7x | -17.8x | 5.5x |
| Thu, 25 Apr 2024 | AU$5.5b | AU$1.2b | -AU$374,923,684.00 | 13.2x | -14.6x | 4.5x |
| Sat, 23 Mar 2024 | AU$5.6b | AU$1.2b | -AU$374,923,684.00 | 15.3x | -15x | 4.6x |
| Mon, 19 Feb 2024 | AU$5.3b | AU$892.3m | -AU$534,729,129.00 | 20.4x | -9.9x | 5.9x |
| Wed, 17 Jan 2024 | AU$5.7b | AU$896.3m | -AU$589,604,392.00 | 21.2x | -9.6x | 6.3x |
| Fri, 15 Dec 2023 | AU$4.5b | AU$896.3m | -AU$589,604,392.00 | 17.1x | -7.7x | 5.1x |
| Sun, 12 Nov 2023 | AU$4.0b | AU$893.0m | -AU$595,020,018.00 | 18.1x | -6.7x | 4.5x |
| Tue, 10 Oct 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19x | -6x | 3.9x |
| Thu, 07 Sep 2023 | AU$3.7b | AU$900.3m | -AU$587,952,018.00 | 19.5x | -6.3x | 4.1x |
| Sat, 05 Aug 2023 | AU$4.1b | AU$999.0m | -AU$624,794,303.00 | 21.1x | -6.5x | 4.1x |
| Mon, 03 Jul 2023 | AU$4.0b | AU$999.0m | -AU$624,794,303.00 | 22.7x | -6.3x | 4x |
| Wed, 31 May 2023 | AU$4.0b | AU$993.2m | -AU$640,306,659.00 | 18.9x | -6.3x | 4.1x |
| Fri, 28 Apr 2023 | AU$4.2b | AU$993.2m | -AU$641,969,868.00 | 19x | -6.6x | 4.3x |
| Sun, 26 Mar 2023 | AU$4.0b | AU$995.9m | -AU$648,651,745.00 | 18.2x | -6.2x | 4.1x |
| Tue, 21 Feb 2023 | AU$3.6b | AU$980.5m | -AU$583,404,566.00 | 16.5x | -6.1x | 3.6x |
| Thu, 19 Jan 2023 | AU$4.1b | AU$948.3m | -AU$544,428,006.00 | 12.9x | -7.6x | 4.3x |
| Sat, 17 Dec 2022 | AU$3.9b | AU$948.3m | -AU$544,428,006.00 | 13.3x | -7.1x | 4.1x |
| Mon, 14 Nov 2022 | AU$4.3b | AU$948.3m | -AU$544,428,005.00 | 12.7x | -8x | 4.6x |
| Wed, 12 Oct 2022 | AU$4.1b | AU$882.1m | -AU$556,645,005.00 | 12.6x | -7.3x | 4.6x |
| Fri, 09 Sep 2022 | AU$4.1b | AU$943.2m | -AU$537,548,829.00 | 12.7x | -7.6x | 4.4x |
| Sun, 07 Aug 2022 | AU$3.9b | AU$819.9m | -AU$339,669,589.00 | 15.6x | -11.6x | 4.8x |
| Tue, 05 Jul 2022 | AU$3.3b | AU$818.2m | -AU$353,932,589.00 | 12.9x | -9.3x | 4x |
| Thu, 02 Jun 2022 | AU$3.9b | AU$818.2m | -AU$353,932,589.00 | 14.8x | -11.1x | 4.8x |
Price to Earnings Ratio
-11.1x
Current Industry PE
- Investors are pessimistic on the Australian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.9x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Revenues for these companies have grown 8.4% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Australian Pharma compare with similar industries?
| AU Market | 0.14% | |
| Healthcare | 0.95% | |
| Pharma | -7.07% | |
| Pharma | -7.07% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AGN Argenica Therapeutics | AU$0.83 | 13.7% +AU$12.8m | 17.7% | PS34.5x | |
| ILA Island Pharmaceuticals | AU$0.21 | 19.4% +AU$7.4m | 216.2% | PS113.2x | |
| NYR Nyrada | AU$0.14 | 28.6% +AU$6.3m | 117.7% | PS17.3x | |
| LTP LTR Pharma | AU$0.33 | 6.6% +AU$3.6m | -27.0% | PS117.7x | |
| MVP Medical Developments International | AU$0.62 | 4.2% +AU$2.8m | 55.0% | PS1.8x |
